Changes in US stocks | CRISPR gene editing company Scribe Therapeutics (SCTX.US) rose more than 59% after entering the US stock market

The Zhitong Finance App learned that on Friday, the CRISPR gene editing company Scribe Therapeutics (SCTX.US), co-founded by Nobel Prize winner Jennifer DouDNA, entered the US stock market, and the opening stock price rose. As of press release, the stock had risen more than 59% to $23.965. The IPO price is $15.

Unlike traditional CRISPR gene editing, Scribe's technology platform uses epigenetic silencing (epigenetic silencing) strategies to target specific genes through an engineered CRISPR system to regulate gene expression without permanently cutting or altering DNA. The company claims that this method has significant safety advantages and can expand the applicable patient population.

The company's core drug candidate STX-1150 targets the PCSK9 gene. By epigenetically silencing PCSK9 gene expression, STX-1150 aims to achieve long-lasting low density lipoprotein cholesterol (LDL-C) reduction. In preclinical studies on non-human primates, STX-1150 achieved up to 90% inhibition of PCSK9 and a maximum LDL-C reduction of 68%. LDL-C reduction of more than 50% was achieved at the lowest dose, and lasted more than 22 months.